Eli Lilly and (LLY) SC 13D Prevail Therapeutics / ELI LILLY & Co ownership change

Exhibit 99.1

Joint Filing Agreement

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.0001 per share, of Prevail Therapeutics Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement this 22nd day of December, 2020.

ELI LILLY AND COMPANY

/s/ Joshua L. Smiley

Name: Joshua L. Smiley

Title: Senior Vice President and Chief Financial Officer

TYTO ACQUISITION CORPORATION

/s/ Kenneth L. Custer

Name: Kenneth L. Custer

Title: President